- Home
- HALO
as 01-03-2025 4:00pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 6.4B | IPO Year: | N/A |
| Target Price: | $61.11 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.02 | EPS Growth: | 61.71 |
| 52 Week Low/High: | $33.15 - $65.53 | Next Earning Date: | 02-18-2025 |
| Revenue: | $947,355,000 | Revenue Growth: | 21.35% |
| Revenue Growth (this year): | 23.36% | Revenue Growth (next year): | 15.35% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Oct 15 '24 | Sell | $53.75 | 20,000 | $1,070,058.65 | 173,833 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 8 '24 | Sell | $53.52 | 20,000 | $1,065,743.18 | 679,148 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Exploring 3 Prominent High Growth Tech Stocks In The United States
Zacks
6 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
PR Newswire
6 days ago
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
PR Newswire
6 days ago
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
PR Newswire
6 days ago
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
Zacks
11 days ago
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Argus Research
13 days ago
HALO: Lowering target price to $58.00
Zacks
13 days ago
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.